US Stock Insider Trading | Syndax discloses 3 insider transactions on February 6

K-LinePoet · 2026-03-07T05:26:48+00:00

On February 6, 2026, Syndax disclosed insider trading, with Director Metzger selling 7,412 shares at $20.62 each, totaling $152,800. Executive Goldan bought 1,219 shares on January 30 and sold 2,082 shares on February 6. Syndax is a biopharmaceutical company focused on innovative cancer therapies.

K-LinePoet

2026-03-07 05:26:48

Abstract generation in progress

On February 6, 2026, Syndax (SNDX) disclosed three insider trading transactions. Director Metzger Michael A sold 7,412 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Director	Metzger Michael A	February 6, 2026	Sell	7,412	20.62	$152,800
February 6, 2026	Executive	Goldan Keith A.	January 30, 2026	Buy	1,219	8.48	$10,300
February 6, 2026	Executive	Goldan Keith A.	February 6, 2026	Sell	2,082	20.62	$42,900
September 8, 2025	Director	Metzger Michael A	September 8, 2025	Sell	157,300	16.41	$2,582,000
September 8, 2025	Director	Metzger Michael A	September 8, 2025	Buy	157,300	10.90	$1,714,600
August 18, 2025	Director	Podlesak Dennis	August 18, 2025	Buy	57,600	7.20	$414,700
August 18, 2025	Director	Podlesak Dennis	August 18, 2025	Sell	19,200	15.84	$304,200
August 14, 2025	Director	Podlesak Dennis	August 14, 2025	Sell	19,200	14.19	$272,500
August 15, 2025	Director	Podlesak Dennis	August 15, 2025	Sell	19,200	15.54	$298,400
July 31, 2025	Executive	Goldan Keith A.	July 31, 2025	Buy	1,226	8.43	$10,300

[Company Profile]

Syndax Pharmaceuticals, Inc. was incorporated on October 11, 2005, under the laws of Delaware. The company is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The company is developing revumenib, a potent, selective small-molecule inhibitor of menin-MLL interaction, for the treatment of KMT2A rearranged or KMT2A-r, also known as mixed lineage leukemia rearrangement or MLLr, including acute lymphoblastic leukemia (ALL), acute leukemia, and acute myeloid leukemia (AML), as well as NPM1-mutated AML.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.